Latest news with #EliLilly&Company
Yahoo
16-05-2025
- Health
- Yahoo
Alopecia Areata: Market Trends, Regulatory Framework, Clinical Trial Analysis, Epidemiology Analysis, Market Dynamics, Competitive Landscape 2025-2035
Includes Detailed Profiles of Industry Giants Eli Lilly & Company, Pfizer, Sun Pharmaceutical Industries, Arcutis Biotherapeutics, Bristol-Myers Squibb, AbbVie, Regeneron Pharmaceuticals, and Aclaris Therapeutics Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Alopecia Areata Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has been added to global market for alopecia areata treatments has experienced substantial growth due to increasing awareness, advancements in medical research, and the introduction of novel therapeutic options. One of the notable examples of current treatments is JAK inhibitors like Ritlecitinib (brand name Litfulo), which received approval by the U.S. FDA for the treatment of alopecia areata in adolescents. This approval marked a significant advancement, given the earlier limited treatment options available for those suffering from this of the key drivers of the alopecia areata market is increasing prevalence of alopecia areata. Alopecia areata affects around 2% of the global population, and its prevalence has been steadily increasing. Environmental factors like stress, pollution, and lifestyle changes are contributing to this rise. The increasing incidence of autoimmune disorders overall also means more individuals are prone to developing alopecia areata. For instance, data from the American Academy of Dermatology estimates that approximately 6.8 million people in the U.S. alone have been affected by some form of traditional treatments like corticosteroids and topical immunotherapy have been somewhat effective, but the market is now being transformed by novel therapies such as JAK inhibitors, which block the pathways involved in the autoimmune attack on hair follicles. One such breakthrough is Dupixent (dupilumab), a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, which has also shown promise for patients with alopecia areata. The approval of Ritlecitinib for alopecia in adolescents in 2023 is another example of how targeted therapies are creating new hope for those affected by the the market's growth, there are several challenges that hinder the wider adoption and accessibility of treatments. Advanced treatments such as biologics (e.g., Ritlecitinib and Dupixent) are often expensive, with some costing thousands of dollars per treatment cycle. This high cost of treatment limits access for many patients, particularly in developing regions where healthcare budgets are constrained. The cost barrier is significant in countries outside the U.S. and Europe, where access to biologics is more limited. The high cost of Dupixent, for example, is a point of concern for patients seeking affordable not all patients respond the same way to therapies. While JAK inhibitors have shown great promise for some individuals with alopecia areata, they may not work equally well for everyone. The variability in patient responses has led to the need for personalized treatment plans, which complicates the management of the condition and may increase healthcare addition, many regions, particularly in Africa, Asia, and Latin America, have limited access to newer treatments due to logistical, financial, and infrastructural barriers. Although global healthcare access is improving, the availability of cutting-edge treatments like JAK inhibitors remains a challenge in these underserved Segmentation Segmentation 1: by Drug Class Corticosteroids JAK (Janus Kinase) Inhibitors Others Segmentation 2: by Region North America Europe Asia-Pacific The alopecia areata market is experiencing several key emerging trends. One notable trend is the rise of personalized medicine, where treatment plans are tailored to an individual's genetic profile, disease progression, and response to therapy. Biotech companies are increasingly investing in genetic research and biomarkers to identify which patients will benefit most from specific treatments. Another trend is the growing demand for non-invasive therapies, such as topical corticosteroids, minoxidil solutions, and low-level laser therapies. These options are becoming more popular due to their reduced side effects and ease of use, offering more affordable and accessible solutions, especially in regions with limited access to biologics. As healthcare access expands globally, biologic therapies like JAK inhibitors are also gaining traction in emerging markets, with pharmaceutical companies working to improve accessibility through patient assistance programs and distribution conclusion, the Alopecia Areata (AA) market is positioned for continued growth, driven by advancements in biologic therapies, rising awareness, and increased healthcare access worldwide. Although challenges such as high treatment costs and variability in treatment response remain, the emergence of new therapies, personalized medicine, and the global expansion of access to effective treatments are poised to enhance the management of alopecia areata. The market is also benefiting from the growing emphasis on mental health and the psychological impact of hair loss, leading to more patient-centered care. As innovation continues, both large pharmaceutical companies and smaller biotech firms will drive competition and improve the quality of life for individuals living with alopecia Topics Covered1. Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Clinical Trial Analysis1.5 Epidemiology Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Alopecia Areata Market, by Drug Class, ($Million), 2023-20352.1 Corticosteroids2.2 JAK (Janus Kinase) Inhibitors2.3 Others3. Global Alopecia Areata Market, by Region, ($Million), 2023-20353.1 North America3.1.1 Key Findings3.1.2 Market Dynamics3.1.3 Market Sizing and Forecast3.1.3.1 North America Alopecia Areata Market, by Country3.1.3.1.1 U.S.3.2 Europe3.2.1 Key Findings3.2.2 Market Dynamics3.2.3 Market Sizing and Forecast3.2.3.1 Europe Alopecia Areata Market, by Country3.2.3.1.1 Germany3.2.3.1.2 U.K.3.2.3.1.3 France3.2.3.1.4 Italy3.2.3.1.5 Spain3.3 Asia Pacific3.3.1 Key Findings3.3.2 Market Dynamics3.3.3 Market Sizing and Forecast3.3.3.1 Asia Pacific Alopecia Areata Market, by Country3.3.3.1.1 Japan4. Global Alopecia Areata Market: Competitive Landscape and Company Profiles4.1 Key Developments and Strategies4.1.1 Mergers and Acquisitions4.1.2 Synergistic Activities4.1.3 Business Expansions and Funding4.1.4 Product Launches and Approvals4.1.5 Other Activities4.2 Company Profiles4.2.1 Eli Lilly and Company4.2.1.1 Overview4.2.1.2 Top Products / Product Portfolio4.2.1.3 Target Customers/End-Users4.2.1.4 Key Personnel4.2.1.5 Analyst View4.2.2 Pfizer Inc.4.2.3 Sun Pharmaceutical Industries Ltd.4.2.4 Arcutis Biotherapeutics4.2.5 Bristol-Myers Squibb4.2.6 AbbVie4.2.7 Regeneron Pharmaceuticals4.2.8 Aclaris TherapeuticsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


WebMD
13-05-2025
- Health
- WebMD
Why Mounjaro Tops Ozempic for Weight Loss
May 12, 2025 – Turns out, two really is better than one – at least when it comes to weight loss drugs. In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who took semaglutide (Ozempic, Wegovy). Semaglutide is a GLP-1 agonist that boosts the hunger-suppressing hormone GLP-1. Tirzepatide is a dual agonist, targeting both GLP-1 and GIP. That means it acts on two hormone pathways, while semaglutide works on one. "We've learnt over the past 20 years or so that you can overcome the plateau effect with obesity drugs if you can add in drugs with mechanisms that are completely different," said Louis J. Aronne, MD, who led the study and is also the director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City. "This is exactly what we see here." In the study, people taking tirzepatide lost about 20% of their body weight, while those taking semaglutide lost around 14%. They also were more likely to hit big weight loss goals – among those who lost 25% or more body weight, twice as many (32%) were on tirzepatide compared with semaglutide (16%). The findings were presented Sunday at the European Congress on Obesity 2025 in Spain, and published in The New England Journal of Medicine on the same day. The trial was sponsored by Eli Lilly & Company, the maker of tirzepatide. "They're both very good medications," said David Horner, MD, of the University of Copenhagen in Denmark, who was not involved in the study. "One is not in doubt that tirzepatide has a greater weight loss benefit from the data. We're comparing a very good drug with a very good drug." First Head-to-Head Comparison Between Two Weight Loss Drugs Both tirzepatide and semaglutide have helped people lose weight in earlier studies, but this is the first time they've been compared side by side. Of the 751 people in the study, half took tirzepatide and half took semaglutide. Both groups received weekly shots for 72 weeks, using the highest dose they could handle without strong side effects. Most people in the study were women in their mid-40s. Most were White. Everyone had struggled with their weight for many years – 16 years, on average – and had tried and failed to lose weight through diet alone. Beyond the weight loss results, tirzepatide also helped people shrink their waistlines by an extra 2 inches – by 7 inches, versus 5 inches for semaglutide. That kind of difference is "clinically meaningful and has been shown to reduce blood pressure and other metabolic parameters," Aronne said. Sure enough, people on tirzepatide saw greater improvements in key health markers like blood pressure, blood sugar, insulin, and cholesterol. "In general, the more weight someone loses, then the better the metabolic parameters will be," Aronne said. Side effects were common and were mostly mild stomach problems like nausea or diarrhea, but few people stopped taking the medicine because of them, he said – only about 6% on tirzepatide and 8% on semaglutide. Of course, the right medicine for each patient depends on a lot of things – including insurance coverage and doctor recommendations – not just which one works best in studies, said Horner.
Yahoo
09-04-2025
- Business
- Yahoo
Eli Lilly & Company (LLY): Among Defensive Stocks Billionaire Ken Fisher Is Betting On
We recently published a list of . In this article, we are going to take a look at where Eli Lilly & Company (NYSE:LLY) stands against other defensive stocks Billionaire Ken Fisher is betting on. Ken Fisher, an American billionaire investor, author, and financial analyst, founded and runs Fisher Asset Management. He is a world-renowned investment manager recognized for his contrarian approach and strong belief in capitalism. With an estimated net worth of more than $11.2 billion, he ranks among the world's wealthiest billionaires. The son of famed investor Philip Fisher, also known as the 'Father of Growth Investing', he coupled his father's growth philosophy with a data-driven value mindset. Long before he became a popular name in the financial industry, Fisher made waves in the 1980s with a revolutionary idea: utilizing the Price/Sales ratio as a major tool for spotting bargain firms. Fisher noted that earnings are frequently erratic, particularly over short periods. Companies may report lower earnings on account of temporary issues such as R&D spending or accounting adjustments. Sales, on the other hand, are more steady and offer a better understanding of a company's business strength. Anyone that follows Fisher knows that he is one of the market's most outspoken pundits. He thinks that, while political developments might elicit strong emotions, they rarely affect the market's long-term direction. According to Fisher, bull markets often end as a result of either unrestrained investor enthusiasm or an unforeseen economic shock with global implications. Interestingly, his views on several subjects, notably tariffs, appear to have evolved. Fisher has previously downplayed the potential impact of President Trump's tariffs, stating that they may not be fully enforced or be in place for as long as anticipated. He also stressed that businesses are highly adaptable to changing economic policies, which he felt may help reduce long-term harm. However, in a recent post on X, the billionaire criticized the government's plan to impose wide tariff measures: 'What Trump unveiled Wednesday is stupid, wrong, arrogantly extreme, ignorant trade-wise and addressing a non-problem with misguided tools. Yet, as near as I can tell it will fade and fail and the fear is bigger than the problem, which from here is bullish.' Over the last two years, the United States has dominated global markets, propelled by large growth stocks in the technology and technology-related communication services sectors, which accounted for more than 40% of US market capitalization, significantly exceeding the rest of the world's 11%. These firms have greatly increased US returns, but Europe, where such equities account for less than 10% of total market capitalization, missed this edge. Europe's rising stock presence is primarily restricted to luxury products, which struggled in 2024 as Asian buyers cut spending. As a result, Europe underperformed significantly during the two-year period, returning only 24.1% compared to the US's 60.3%. Now, however, Europe is taking the lead, and its leading sectors—primarily value stocks linked to economic cycles rather than long-term trends—are primed to benefit, a sentiment that Ken Fisher echoes himself: 'This should be the first year in quite some years where value beats growth. And as that happens, the US lags the non-US world, and particularly Europe, which is so heavily value laden. So that's been my core forecast. That will remain my core forecast until I see some big change or something different that should make me change my mind. But I babble on these videos pretty much every month, so you can hear that if it ever happens this year. Otherwise, that's my view. I think it'll be another big year in the market with global 20% kind of returns.' For this article, we picked defensive companies from Fisher Asset Management's 13F portfolio as of the end of the fourth quarter of 2024. The following firms have low beta values (<1), consistent dividend histories, and robust businesses. Additionally, we have mentioned the hedge fund sentiment around each stock, as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Eli Lilly & Company (NYSE:LLY) is a notable global pharmaceutical firm that develops, manufactures, and sells a variety of pharmaceuticals. It was founded in 1876 and has since evolved to be one of the leading names in the global pharmaceutical industry. On March 25, Bernstein analysts maintained an Outperform rating on Eli Lilly & Company (NYSE:LLY), with a $1,100 price target. The backing comes as competitor Novo Nordisk works on developing a medicine similar to Eli Lilly's Retatrutide, a high-efficacy asset in the company's pipeline. Despite the chance that Novo's medicine might provide better weight loss results, Bernstein's study supports Eli Lilly's market lead with Retatrutide. The company's revenues increased by 45% in the fourth quarter of 2024 to $13.53 billion, owing to increased demand for Mounjaro and Zepbound. Meanwhile earnings per share increased dramatically by 102% to $4.88. Overall, LLY ranks 2nd on our list of defensive stocks billionaire Ken Fisher is betting on. While we acknowledge the potential for LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than LLY but trades at less than 5 times its earnings, check out our report about the . READ NEXT: and . Disclosure: None. This article is originally published at .